Last edition
News about "Fosun Pharma"
Accro Bioscience and Fosun Pharma Enter Licensing Deal for AC-201 in Greater China
Accro Bioscience has granted Fosun Pharma exclusive rights to develop, manufacture, and commercialise AC-201 — its independently developed, highly selective TYK2/JAK1 inhibitor — in Greater China (including the Chinese Mainland, Hong Kong SAR, and Macau SAR).
Fosun Pharma | 01/09/2025 | By Dineshwori
Fosun Pharma Industrial has signed a global License Agreement with Expedition Therapeutics Inc., granting the US-based biotechnology company the rights to develop, manufacture, and commercialise its investigational respiratory drug XH-S004 in all regions worldwide, excluding the Chinese Mainland, Hong Kong SAR, and Macau SAR.
Fosun Pharma | 13/08/2025 | By Dineshwori
China's Fosun to build African drug manufacturing plant with help from World Bank
China’s Fosun Pharma plans to build a facility in the Ivory Coast to manufacture anti-malaria drugs and antibacterial medicines with the help of a 100 million euro ($106 million) loan from the International Finance Corporation (IFC).
Fosun Pharma | 07/06/2023 | By Sudeep Soparkar | 552
China-based Fosun Pharma taps big buyout for Hyd-based Gland Pharma
Gland specialises in injectable drugs such as antibiotics, oncology and cardiology treatments and has a presence in about 60 countries
Fosun Pharma | 13/12/2022 | By Sudeep Soparkar | 498
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy